Skip to content

Clinical diagnosis of moderate-to-severe plaque psoriasis for at least 6 months prior to study enrollment

Clinical diagnosis of moderate-to-severe plaque psoriasis for at least 6 months prior to study enrollment 1

This study has been withdrawn prior to enrollment. Clinical diagnosis of moderate-to-severe plaque psoriasis for at least 6 months prior to enrollment;. Additional one year results from the LIBERATE study will be presented, including effect on difficult-to-treat areas (scalp and nails), pruritus (itching) and Dermatology Quality-of-Life Index scores, as well as a cost-per-responder analysis of 16 weeks of treatment. ESTEEM 1 and 2 are two large pivotal phase 3 randomized, placebo-controlled studies evaluating OTEZLA in patients with a diagnosis of moderate to severe plaque psoriasis for at least 12 months prior to screening, and who were also candidates for phototherapy and/or systemic therapy. View Psoriasis and Psoriatic Disorders clinical trial results here. The study enrolled 166 subjects, 42 receiving BI 655066 180mg, 41 receiving BI 655066 90mg, 43 subjects receiving BI 655066 18mg, and 40 receiving ustekinumab 45mg/90mg.

Clinical diagnosis of moderate-to-severe plaque psoriasis for at least 6 months prior to study enrollment 2Adults 18 years and older with moderate to severe plaque psoriasis. At study visits, all participants will answer a questionnaire, have blood taken, and get their treatment. Clinical diagnosis of psoriasis for at least 6 months as determined by subject interview of his/her medical history and confirmation of diagnosis through physical examination by Investigator. Stable plaque psoriasis for at least 2 months before Screening and at Baseline (Week 0) as determined by subject interview of his/her medical history. Adults 18 years and older with moderate to severe plaque psoriasis. At study visits, all participants will answer a questionnaire, have blood taken, and get their treatment. Clinical diagnosis of psoriasis for at least 6 months as determined by subject interview of his/her medical history and confirmation of diagnosis through physical examination by Investigator. Cannot avoid UVB phototherapy for at least 14 days prior to the Baseline (Week 0) visit. 6. This study aimed to investigate the immunogenicity of ustekinumab and its clinical consequences in psoriasis. Levels of anti-ustekinumab antibody (AUA) and serum ustekinumab concentration were measured respectively by radioimmunoassays and enzyme-linked immunoassays respectively, and correlated to clinical data and Psoriasis Area and Severity Index (PASI).

This study enrolled patients with MSPP actively seeking care. Moderate to severe plaque psoriasis medication use in the past 6 months. Learn more about all our work via the Feinberg Office of Research Clinical Trials page. Care of Sutured Wounds This study is enrolling participants by invitation only. Efficacy of Baricitinib in Patients with Moderate-to Severe-Atopic Dermatitis18 and older. 18 to 65 year old who have a diagnosis of plaque psoriasis for at least 6 months and are willing to forgo other available psoriasis therapies, live vaccines, and pregnancy during the trial. SPIRIT evaluated 249 patients with plaque psoriasis for at least 6 months. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. 1,2 Treatment for latent infection should be initiated prior to treatment with REMICADE.

Nih Clinical Center Search The Studies: Study Number, Study Title

CIMZIA is not currently approved for the treatment of psoriasis by any regulatory authority worldwide. CIMZIA Phase 3 program for adult patients with moderate-to-severe plaque psoriasis, stated Tom Wiggans, chairman and chief executive officer of Dermira. (6-MP) concomitantly with a TNF blocker at or prior to diagnosis. Have a diagnosis of active PsA for at least 6 months. Have active psoriatic skin lesions (plaque) or a documented history of plaque Ps. Have used DMARDs other than MTX, leflunomide, sulfasalazine, or hydroxychloroquine in the 8 weeks prior to study entry. Currently enrolled in a placebo-controlled BENLYSTA (belimumab) clinical trial or a continuation protocol where belimumab is used as an investigational agent. You may qualify for a clinical research study enrolling now. The CIMPACT study is the third and final clinical trial of the CIMZIA Phase 3 development program in moderate-to-severe chronic plaque psoriasis to complete enrollment, following the completion of enrollment for the CIMPASI-2 Phase 3 trial in September 2015 and CIMPASI-1 Phase 3 trial in November 2015. While any marketing approval will be based on the overall results of the trials, the company expects that marketing approval for CIMZIA in moderate-to-severe chronic plaque psoriasis in the U. (6-MP) concomitantly with a TNF blocker at or prior to diagnosis. Results from various clinical trials including the REVEAL, CHAMPION, and BELIEVE are included in this review. Eligibility criteria included adult patients with moderate to severe plaque psoriasis for at least 6 months, and stable plaque psoriasis for at least 2 months before screening. Prior treatment with topical, systemic, or phototherapy was acceptable after a washout period, and all patients were screened for latent tuberculosis upon entry. The study population included 526 High-Need patients (342 efalizumab, 184 placebo). Objective: To evaluate the impact of efalizumab on HRQOL and other patient-reported outcomes in patients with moderate to severe plaque psoriasis. During the study period, but before results were available, a protocol amendment restricted enrollment to patients meeting the definition of High-Need patients (Dubertret L, Sterry W, Bos JD, et al. All patients enrolled were 18 to 75 years of age with at least a 6-month history of plaque psoriasis, with involvement of 10 of total body surface area (BSA), had a minimum PASI of 12.

Health Care Resource Use, Productivity, And Costs Among Patients With Moderate To Severe Plaque Psoriasis In The United States

This study is investigating the efficacy and tolerability of subcutaneous tildrakizumab MK 3222, SCH 900222; Merck and Co in patients with moderate to severe.